Meto Review
Best for: insurance-accepting metabolic telehealth with compounded sema/tirz, lab monitoring, all 50 states
Meto is an insurance-accepting metabolic telehealth platform offering compounded semaglutide and compounded tirzepatide, prescribed after clinician-ordered lab work. The platform matches patients with board-certified specialists — including endocrinologists, obesity medicine physicians, dietitians, and metabolic health coaches — within minutes, and manages all billing, prior-authorization, and insurance paperwork for major insurers (Blue Cross, Anthem, United Healthcare, Aetna). Most insured patients pay $0–50 per visit; self-pay rates exist but are not publicly disclosed.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Not disclosed
Lab work
Included
Coaching
Included
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Meto is a solid telehealth option with balanced features and pricing.
Meto at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- What's included
- Medication · Consult · Labs · Coaching
- FDA status
- No FDA warning letter on record
How we scored Meto
Each dimension is scored algorithmically from Meto’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
6.3/10Meto does not post a standard monthly cash price up front, so cost transparency is limited — confirm the ongoing rate before you commit.
Effectiveness25%
8.1/10Meto offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.4/10Online intake and platform experience — consult included in the price; 8 platform features disclosed.
Trust & Safety15%
7.3/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-07-04).
Accessibility10%
8.6/10Meto treats patients in all 50 states. Insurance pathways are offered for eligible patients.
Support10%
7.2/10Coaching/dietitian access included.
How we verified this Meto review
Last checked 2026-07-04- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications Meto offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
What we like
- Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
- Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
- Matches patients with endocrinologists and obesity medicine specialists within minutes
- Offers compounded semaglutide and tirzepatide with board-certified physician oversight
- Handles all prior-auth paperwork; provider location pages exist for all 50 US states
Watch-outs
- Medication pricing fully gated behind quiz — no public cash price for sema or tirz
- Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
- No LegitScript certification or named compounding pharmacy found on any public page
- Company leadership and clinical team not disclosed publicly
- Self-pay cash pricing exists per site copy but is not published anywhere
Is Meto worth it? Our verdict
Meto positions itself around one thing: insurance-accepting metabolic telehealth with compounded sema/tirz, lab monitoring, all 50 states. Coaching and follow-up are part of the package, not an upsell.
What gives Meto its own flavor: Insurance Accepted, Lab Monitoring Required, and Metabolic Specialist Matching.
How much Meto actually costs
Meto doesn't post a standard monthly cash price publicly. Start a consultation to get an exact quote, and confirm the ongoing rate — not just any first-month offer — before you commit.
Medications: what Meto prescribes
Meto prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the pair backed by the largest published weight-loss trials.
Who Meto is best for — and who should skip it
A good fit if you…
- want coaching and follow-up included, not sold separately.
- live anywhere in the US and want guaranteed access.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
Meto treats patients in all 50 states. We found no FDA warning letters on file for the provider. We explain how we weigh medical oversight and compliance in our scoring methodology.
Bottom line
Meto could be worth a look, but it doesn't publish a standard price up front — get a quote and confirm the ongoing rate before deciding, and compare it against the alternatives below. If you're comparison-shopping, Telos Rx is one of the closest alternatives we track — worth a look before deciding.
Ready to start with Meto?
See current pricing and start your free consultation.
Alternatives to Meto
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Meto review:
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
Ready to start with Meto?
See current pricing and start your free consultation.